1.Advance in neoadjuvant chemotherapy for colorectal liver metastasis
Ganlu ZHANG ; Junbo YUAN ; Changlin ZHAO
Journal of International Oncology 2010;37(11):859-862
Neoadjuvant therapy has been gradually applied to the treatment of colorectal liver metastasis in recent years. Many clinic researches indicate neoadjuvent chemotherapy, neoadjuvent radiotherapy and neoadjuvent chemoradiotherapy can improve surgical reaction rate and radical rate of colorectal liver metastasis,and can shrink the primary tumor and metastasis, improve the resection rate and sphincter preservation rate, and reduce the recurrence rate of locally advanced lower rectal cancer. Neoadjuvent therapy has great clinical practical value in the multi-modality treatment for colorectal metastasis.
2.Correlation between the expression of C-terminal tensin-like protein and the prognosis of hepatocellular carcinoma
Jia CHEN ; Yan ZHANG ; Ganlu DENG ; Junli MA ; Xiaoling WU ; Yanling QU ; Shan ZENG
Journal of Central South University(Medical Sciences) 2014;(12):1233-1239
Objective: To explore the correlation between the expression of C-terminal tensin-like protein (CTEN) and the prognosis of hepatocellular carcinoma (HCC). Methods: Using immunohistochemistry, we detected CTEN protein level in samples of primary lesion and adjacent non-tumor lesion collected from 240 patients with HCC. The relationship between CTEN expression and clinicopathology, 5 year recurrent-free survival, or overall survival was evaluated by Chi-square test, Kaplan-Meier, or Cox regression analysis. Results: High CTEN expression was detected in 55% of hepatocellular carcinoma tissues and 20%of adjacent carcinoma tissues (P<0.001). CTEN expression was positively correlated with tumor diameter (P=0.022), venous invasion (P=0.007) or TNM stages (P=0.022). Five-year recurrence-free survival time (P<0.001) and overall survival time (P<0.001) in patients with high CTEN expression were signiifcantly less than those in patients with low CTEN expression. Multivariate Cox regression analysis revealed that the CTEN expression was an independent prognostic marker for HCC (all P<0.05). Conclusion: CTEN protein may play a role in the genesis and development of HCC, and it can function as a prognostic marker.
3.Expression of RASAL2 in hepatocellular carcinoma and the clinical significance.
Hong SHEN ; Xiaoling WU ; Yan ZHANG ; Ganlu DENG ; Junli MA ; Yanling QU ; Shan ZENG
Journal of Central South University(Medical Sciences) 2015;40(3):250-255
OBJECTIVE:
To detect the expression of RA SAL2 in patients with hepatocellular carcinoma (HCC), and to investigate the association of RASAL2 expression with pathological characteristics and prognosis.
METHODS:
Immunohistochemical SP method was used to detect the expression of RA SAL2 in 164 samples of HCC tissue and the adjacent tissue. Th e association of RA SAL2 expression with clinical features and prognosis was analyzed.
RESULTS:
The expression of RASAL2 in adjacent tissue was significantly increased compared to that in HCC tissue (P<0.001). The expression level of RASAL2 was associated with the degree of differentiation, tumor TNM stage and vascular invasion (P<0.001), but not associated with the level of AFP, tumor size, or the number of nodules (P>0.05). The 5 years recurrence-free survival (RFS) in patients with low expression of RASLA2 was significantly reduced compared with that in patients with high expression of RASLA2 (P<0.001). Cox analysis showed that low expression of RASLA2 was the independent factor for recurrence and death in HCC patients after surgery (P<0.001).
CONCLUSION
Low expression of RRASAL2 is significantly associated with the poor prognosis of HCC, which is an independent factor for HCC prognosis.
Carcinoma, Hepatocellular
;
genetics
;
metabolism
;
Carrier Proteins
;
genetics
;
metabolism
;
Humans
;
Liver Neoplasms
;
genetics
;
metabolism
;
Neoplasm Recurrence, Local
;
Prognosis